INTRODUCTION
This article describes the case of a patient with cutaneous ulcers who was found to have systemic Langerhans cell histiocytosis (LCH). This article includes the clinical, histology, and electron microscopy images, in addition to a description of the presentation, workup, and management of this rare disease in this patients, with a review of the literature.
CASE
A 55-year-old man presented to the Veterans Affairs New York Harbor Hospital for evaluation of ulcers in his left inguinal and intergluteal folds that had been progressing over several months (Fig 1) . During a screening colonoscopy for workup of worsening anemia 1 month prior, a polyp was excised and pathology revealed an unusual histiocytic infiltration seen on pathology. Positron emission tomographyecomputed tomography revealed hypermetabolic cutaneous foci involving the left inguinal and perianal regions corresponding to sites of cutaneous ulceration. The patient described the ulcers as asymptomatic and gradually enlarging in size. He did not have drainage or pain from the affected areas. He also had no sexual activity, nausea, vomiting, abdominal pain, blood in stool, fevers, weight loss, or other constitutional symptoms.
Examination of the patient's left inguinal fold and intergluteal cleft revealed well-demarcated ulcers with rolled cobblestoned borders and fibrinous granulation tissue at the ulcer base. The lesions were nontender on palpation without an associated odor, erythema, or vesicles. There was shotty inguinal lymphadenopathy. On the soft oral palate, exophytic verrucous plaques were noted.
A complete blood count with differential analysis, basic metabolic panel, and rapid plasma reagin were unremarkable. On histopathologic examination, both skin and colon biopsies showed a dense proliferation of histiocytes and lymphocytes. Immunostaining was positive for S100, CD1a, and CD4 and weakly positive for CD45 and CD68 (Fig 2) . CD20 and CD3 were negative. Electron microscopy of the skin biopsy showed Birbeck granules within the cytoplasm of a Langerhans cell (Fig 3) . The skin lesion was negative for BRAF V600 mutations, including V600E, V600K, V600D, V600R, V600A, V600G, and V600M. A bone marrow biopsy was negative for CD1a and S100.
DISCUSSION
The diagnosis was the systemic LCH in an adult patient. LCH represents a spectrum of diseases characterized by clonal proliferations of Langerhans cells. The current clinical classification of LCH is based on the extent of involvement of disease, ranging from single system to progressive multisystem LCH. 2 LCH is most commonly diagnosed in pediatric patients 1-3 years of age.
3 A large case series reported 66%-90% of patients presenting before 18 years of age. [4] [5] [6] LCH has an estimated annual incidence of 5 cases per 1 million children and 1-2 cases per 1 million adults. In children, LCH is more common in boys, with an approximate ratio of 2:1; in adults, there is a slight female predominance. 5 When systemically involved, LCH tends to affect the skeletal, cutaneous, lymphoreticular, pulmonary, and pituitary gland systems. Involvement of reproductive organs, the central nervous system, the gastrointestinal tract has also been described. 1 LCH with gastrointestinal manifestations is exceedingly rare, with only 4 reported cases in the current literature. One report describes a 49-year-old Japanese woman with sessile protuberances on her stomach wall on endoscopy and biopsy revealing characteristic features of LCH. 7 Three other patients have been described as having gastrointestinal involvement, and each were treated successfully with surgical resection. 5 The pathogenesis of LCH has yet to be elucidated; however, immune dysregulation has been implicated. 8 The detection of clonal populations of histiocytes in different forms of LCH suggests a neoplastic etiology due to mutations of bone marrow precursor cells. 9 A majority (57%) of LCH specimens were found to contain the BRAF V600E mutation, further supporting a neoplastic origin and raising the possibility of using BRAF inhibitors for future LCH therapy. 10 However, the skin lesion in our patient was negative for the BRAF V600 mutations V600E, V600K, V600D, V600R, V600A, V600G, and V600M.
The pathology of LCH can be as variable as the clinical presentation. Classically, LCH involves a proliferation of Langerhans cells in the papillary dermis with reniform (kidney-shaped) nuclei. Often, Langerhans cells can infiltrate the epidermis with interface changes. Dermal Langerhans cells are typically admixed with mast cells, neutrophils, lymphocytes, plasma cells, and eosinophils. LCH lesions were positive for CD1a, Langerin (CD207), and S100 on immunostaining, and lacked classic macrophage/ monocyte markers, such as CD68 or HAM6. Electron microscopy revealed Birbeck granules, which are racquet-shaped cytoplasmic structures found in Langerhans cells (Fig 3) . Presently, electron microscopy is rarely performed, given the ease of testing via CD1a and Langerin immunostaining.
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The differential diagnosis for inguinal and intergluteal ulcers includes inflammatory conditions such as pyoderma gangrenosum, cutaneous Crohn disease, Behcet disease, and vasculitis; infectious etiologies such as bacterial (Streptococcus, Treponema, Haemophilus, Klebsiella), viral (herpes simplex virus), fungal, and parasitic; neoplastic disorders including basal cell carcinoma, squamous cell carcinoma, metastases, and extramammary Paget disease; reactions to medications such as hydroxyurea, methotrexate, interferon, and anticoagulants; and exogenous causes such as traumatic or factitial etiologies.
All patients diagnosed with LCH are recommended to have a hematologic, pulmonary, hepatosplenic, renal, and skeletal systemic evaluation to determine the extent of disease involvement. Central nervous system and bone marrow evaluation might be indicated. Treatment of LCH depends on the number and severity of the organ systems involved. For skin disease, topical corticosteroids, topical antimicrobials, phototherapy, and topical nitrogen mustard have been reported in small case series. More extensive cutaneous disease has been treated with thalidomide with reported efficacy. More extensive disease involving multiple organ systems requires systemic therapy. Treatments include vinblastine, etoposide, multidrug chemotherapy, etanercept, cyclosporine, imatinib, radiation, prednisone, and cyclophosphamide alone or in combination. For severe disease, hematopoietic stem cell, liver, or lung transplantation might be required. 1 We report an unusual case of LCH occurring in a male adult with gastrointestinal involvement. In follow-up, the patient was started on systemic therapy with hydroxyurea and gradually increased from 500 mg daily to 1500 mg daily. He reports the lesion on his hard palate has improved with less tenderness when eating. Cutaneous lesions have been stable, with minimal improvement with intralesional steroid injections.
